Longboard Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Longboard Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Longboard Pharmaceuticals: 4 sponsored US clinical trials, 2 recruiting.
Longboard Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Developmental and Epileptic Encephalopathy, with 3 trials.
Upper-quartile sponsor footprint
Longboard Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
NCT05626634
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
NCT05364021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Longboard Pharmaceuticals pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Developmental and Epileptic Encephalopathy (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Longboard Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Longboard Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Longboard Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of Longboard Pharmaceuticals or any single study.
- 2 of Longboard Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Developmental and Epileptic Encephalopathy is the condition Longboard Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Developmental and Epileptic Encephalopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Longboard Pharmaceuticals pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.